On the stock market since 2019, it operates in the world of health and science. It has 321 employees. Now — the numbers.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The sales tempo runs behind the sector. Council score: 2/10.
On our five-subject report card, GLASF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: GLASF is a high-risk stock — not yet profitable, and its future rides on its product catching on.